ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 60 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,989,028 | -22.8% | 222,889 | +2.5% | 0.00% | 0.0% |
Q2 2023 | $7,754,017 | +24.9% | 217,443 | -11.0% | 0.00% | +33.3% |
Q1 2023 | $6,208,801 | -32.5% | 244,441 | +7.8% | 0.00% | -40.0% |
Q4 2022 | $9,194,546 | +25.6% | 226,690 | +2.3% | 0.01% | +25.0% |
Q3 2022 | $7,321,000 | -37.8% | 221,520 | -33.8% | 0.00% | -42.9% |
Q2 2022 | $11,775,000 | -25.1% | 334,422 | -2.2% | 0.01% | 0.0% |
Q1 2022 | $15,718,000 | -2.7% | 341,791 | +40.3% | 0.01% | 0.0% |
Q4 2021 | $16,154,000 | +5.7% | 243,649 | -0.5% | 0.01% | 0.0% |
Q3 2021 | $15,290,000 | -30.7% | 244,914 | -8.1% | 0.01% | -36.4% |
Q2 2021 | $22,061,000 | -22.6% | 266,379 | -38.0% | 0.01% | -26.7% |
Q1 2021 | $28,488,000 | +20.5% | 429,633 | +39.4% | 0.02% | +7.1% |
Q4 2020 | $23,641,000 | +214.1% | 308,106 | +76.3% | 0.01% | +180.0% |
Q3 2020 | $7,527,000 | -11.2% | 174,774 | -10.9% | 0.01% | -16.7% |
Q2 2020 | $8,473,000 | +297.2% | 196,170 | +164.5% | 0.01% | +200.0% |
Q1 2020 | $2,133,000 | -91.4% | 74,172 | -81.1% | 0.00% | -87.5% |
Q4 2019 | $24,873,000 | +133.9% | 392,174 | +3.9% | 0.02% | +128.6% |
Q3 2019 | $10,635,000 | -35.1% | 377,501 | -39.0% | 0.01% | -30.0% |
Q2 2019 | $16,386,000 | +312.6% | 618,421 | +185.7% | 0.01% | +400.0% |
Q1 2019 | $3,971,000 | +703.8% | 216,468 | +443.5% | 0.00% | – |
Q4 2018 | $494,000 | -95.7% | 39,825 | -93.3% | 0.00% | -100.0% |
Q3 2018 | $11,399,000 | +103.8% | 594,676 | +44.6% | 0.00% | +50.0% |
Q2 2018 | $5,594,000 | +227.7% | 411,363 | +73.7% | 0.00% | +100.0% |
Q1 2018 | $1,707,000 | +1299.2% | 236,845 | +605.0% | 0.00% | – |
Q4 2017 | $122,000 | -19.7% | 33,595 | -5.4% | 0.00% | – |
Q3 2017 | $152,000 | -63.1% | 35,501 | -86.1% | 0.00% | – |
Q2 2017 | $412,000 | +357.8% | 255,128 | +412.7% | 0.00% | – |
Q1 2017 | $90,000 | -31.3% | 49,760 | -42.5% | 0.00% | – |
Q4 2016 | $131,000 | -92.9% | 86,550 | -65.7% | 0.00% | -100.0% |
Q3 2016 | $1,856,000 | +216.7% | 252,677 | +128.9% | 0.00% | – |
Q2 2016 | $586,000 | – | 110,393 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |